Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 62   

Articles published

AZN 5,138.80 +80.80 (1.60%)
price chart
AstraZeneca Declines Most in 5 Months on Forecast: London Mover
AstraZeneca Plc, the U.K.'s second-biggest drugmaker, fell the most in five months after saying profit this year will decline as the company prepares to face generic competition to top-selling medicines.
AstraZeneca closing Montreal R&D plant  Globe and Mail
AstraZeneca to cut 7300 jobs worldwide
AstraZeneca India job cuts likely to hurt drug research
New Delhi: Theextensive layoffs at London-listed drug maker AstraZeneca Plc's research outfits have hit India. On 13 February, the firm's Bangalore subsidiary laid off 19 employees—15 of them middle-level and senior scientists involved in the research ...
AstraZeneca Loses Ruling Over 2018 and 2021 Crestor Patents
AstraZeneca Plc lost a U.S. appeals court bid to protect its best-selling drug, Crestor, from generic competition until as late as 2021.
Astra takes brand cancer drug straight to patients
AstraZeneca Plc is selling breast cancer drug Arimidex directly to U.S. patients, offering an option for people who want to pay for the brand instead of generic versions.
Special Report: A prescription for corruption
Officials at drugs companies AstraZeneca Plc, Sanofi SA and Actavis confirmed they were served in July and August 2011 with criminal indictments related to allegedly improper payments to physicians including Borojevic at his state-run institute, and ...
Greek Doctors Battle Hospital Superbug
The drug-resistant K. pneumoniae bacteria have a genetic mutation that allows them to evade such powerful drugs as AstraZeneca Plc's Merrem and Johnson & Johnson's Doribax. A 2010 survey found 49 percent of K. pneumoniae samples in Greece aren't ...
Greece-Germany tension rises, reflects wider European rift
ROME Whether or not Greece secures a new bailout to avoid bankruptcy next month, relations between Athens and Germany look close to breaking point.
Pfizer eyes tie-ups with more Chinese drugmakers
Apart from Pfizer, drugmakers like AstraZeneca Plc (AZN.L), Abbott Laboratories (ABT.N) and Novartis AG NOVN.VX are taking advantage of China's lower costs and enormous pool of scientists to make big investments in R&D in China in recent years.
Fakes Infiltrate Injectable Drugs
13, the FDA also alerted British drug maker AstraZeneca PLC to "a number of cases of illegal importation of oncology drugs into the U.S.
Debt crisis: as it happened - February 2, 2012
Profits are also up at AstraZeneca , although the company has warned that it expects earnings to fall this year as patents on key drugs expire and governments squeeze prices.